Vascularization of Patient-Derived Tumoroid from Non-Small-Cell Lung Cancer and Its Microenvironment
Joseph Seitlinger,
Anasse Nounsi,
Ysia Idoux-Gillet,
Eloy Santos Pujol,
Hélène Lê,
Erwan Grandgirard,
Anne Olland,
Véronique Lindner,
Cécile Zaupa,
Jean-Marc Balloul,
Eric Quemeneur,
Gilbert Massard,
Pierre-Emmanuel Falcoz,
Guoqiang Hua,
Nadia Benkirane-Jessel
Affiliations
Joseph Seitlinger
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Anasse Nounsi
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Ysia Idoux-Gillet
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Eloy Santos Pujol
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Hélène Lê
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Erwan Grandgirard
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), CNRS, UMR 7104, Inserm U 1258, 1 rue Laurent Fries, BP 10142, 67404 Illkirch Graffenstaden, France
Anne Olland
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Véronique Lindner
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Cécile Zaupa
Transgene SA, 400 Boulevard Gonthier d’Andernach-Parc d’Innovation-CS80166, 67405 Illkirch Graffenstaden, France
Jean-Marc Balloul
Transgene SA, 400 Boulevard Gonthier d’Andernach-Parc d’Innovation-CS80166, 67405 Illkirch Graffenstaden, France
Eric Quemeneur
Transgene SA, 400 Boulevard Gonthier d’Andernach-Parc d’Innovation-CS80166, 67405 Illkirch Graffenstaden, France
Gilbert Massard
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Pierre-Emmanuel Falcoz
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Guoqiang Hua
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Nadia Benkirane-Jessel
INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, CRBS, 1 Rue Eugène Boeckel, 67000 Strasbourg, France
Patient-derived tumoroid (PDT) has been developed and used for anti-drug screening in the last decade. As compared to other existing drug screening models, a PDT-based in vitro 3D cell culture model could preserve the histological and mutational characteristics of their corresponding tumors and mimic the tumor microenvironment. However, few studies have been carried out to improve the microvascular network connecting the PDT and its surrounding microenvironment, knowing that poor tumor-selective drug transport and delivery is one of the major reasons for both the failure of anti-cancer drug screens and resistance in clinical treatment. In this study, we formed vascularized PDTs in six days using multiple cell types which maintain the histopathological features of the original cancer tissue. Furthermore, our results demonstrated a vascular network connecting PDT and its surrounding microenvironment. This fast and promising PDT model opens new perspectives for personalized medicine: this model could easily be used to test all therapeutic treatments and could be connected with a microfluidic device for more accurate drug screening.